Cue Biopharma Inc (CUE)
1.245
-0.26
(-17.00%)
USD |
NASDAQ |
Nov 15, 16:00
1.45
+0.20
(+16.47%)
After-Hours: 20:00
Cue Biopharma Research and Development Expense (TTM): 40.49M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 40.49M |
| March 31, 2024 | 41.61M |
| December 31, 2023 | 40.80M |
| September 30, 2023 | 41.25M |
| June 30, 2023 | 38.94M |
| March 31, 2023 | 37.89M |
| December 31, 2022 | 38.58M |
| September 30, 2022 | 38.75M |
| June 30, 2022 | 42.46M |
| March 31, 2022 | 41.63M |
| December 31, 2021 | 41.37M |
| September 30, 2021 | 37.87M |
| June 30, 2021 | 34.10M |
| March 31, 2021 | 33.46M |
| December 31, 2020 | 33.55M |
| Date | Value |
|---|---|
| September 30, 2020 | 32.51M |
| June 30, 2020 | 30.29M |
| March 31, 2020 | 29.04M |
| December 31, 2019 | 27.49M |
| September 30, 2019 | 27.35M |
| June 30, 2019 | 32.36M |
| March 31, 2019 | 30.90M |
| December 31, 2018 | 28.37M |
| September 30, 2018 | 30.57M |
| June 30, 2018 | 24.25M |
| March 31, 2018 | 22.26M |
| December 31, 2017 | 18.90M |
| September 30, 2017 | 11.95M |
| June 30, 2017 | 9.343M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
27.49M
Minimum
Dec 2019
42.46M
Maximum
Jun 2022
36.95M
Average
38.58M
Median
Dec 2022
Research and Development Expense (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 779.92M |
| Arbutus Biopharma Corp | 62.79M |
| GlycoMimetics Inc | 22.89M |
| FibroGen Inc | 185.40M |
| Cidara Therapeutics Inc | 70.46M |